Bringing It Home: Next generation of clinical trials & implications for publication professionals

The COVID pandemic both accelerated adoption of decentralized clinical trials and highlighted the importance of decentralization in making clinical trials more patient-centric. These trials allow for the continuation of research in challenging periods, as we have seen recently with the global pandemic and in times of war. They don’t, however need to be viewed as only a fall back methodology as there are numerous benefits that make decentralized trials a methodological option and not just an alternative. They have the potential to improve patient engagement in research and certainly help with equity, diversity and inclusion.Join us for a conversation about decentralized trials with Craig Lipset. Craig is the Co-founder and Co-chair of the Decentralized Trials & Research Alliance which is the industry's largest non-profit collaboration exclusively focused on the global adoption of decentralized research; he is also a board Vice Chair for MedStar Health Research Institute and Vice President of the Foundation for Sarcoidosis Research. Generously sponsored by MedThink SciCom.